Leuven, Belgium, Thursday, April 8th, 2021 – ArtiQ announces a partnership with Vyaire Medical to bring its ArtiQ.PFT software to hospitals across Europe. Vyaire Medical is recognized and trusted by specialists throughout the global respiratory community for its respiratory diagnostics solutions. The ArtiQ.PFT software automates the interpretation of pulmonary function tests (PFTs) and provides artificial intelligence (AI)-based diagnosis support. This partnership allows hospitals across Europe to gain easy access to a fully integrated solution of both hardware and software that supports their entire PFT workflow from test to diagnosis.
Respiratory diseases, such as COPD, Asthma and ILD, are the leading causes of mortality and disability across the world. Despite significant advances, the unmet diagnostic need remains substantial. In the fight against this problem, ArtiQ dedicated itself to empower medical professionals with artificial intelligence to accurately and timely diagnose lung diseases and help patients suffering from them.
This partnership with Vyaire Medical ensures easy access to the ArtiQ.PFT software for a large number of European hospitals. The latest SentrySuite version provides a fully integrated connection with ArtiQ.PFT into the PFT workflow used in clinical practice today. Next to this technical integration, the Vyaire sales and services teams will bring the ArtiQ software to their large network of hospitals.
“This partnership is an important step forward for ArtiQ, it supports our growth to new markets, and most importantly, it allows all Vyaire customers easy access to AI support for PFT interpretations,” says Marko Topalovic, CEO of ArtiQ.
By joining forces, the two companies bring together ArtiQ’s expertise on respiratory AI and cloud-based solutions and Vyaire’s extended experience and network in pulmonary function testing.
“Vyaire is at the forefront of incorporating the latest digital technology to ensure people’s breathing needs are met. By introducing this technology, we can help clinicians feel confident in their diagnosis at the outset, enhancing their patients’ care from the start,” said Gaurav Agarwal, chief executive officer of Vyaire in the company’s press release.
ArtiQ is a young, dynamic, and innovative spin-off company of the University of Leuven (Belgium). The company was founded in early 2019 by four committed founders with an extensive history in respiratory medicine, medical devices, and artificial intelligence. ArtiQ’s mission is to empower medical professionals with artificial intelligence to accurately and timely diagnose, treat and follow-up patients with lung diseases.